{"schema_version":"secwatch.filing_event.v1","accession":"0001638833-23-000067","form_type":"8-K","ticker":"SGRY","cik":"0001638833","company_name":"Surgery Partners, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.782723+00:00","generated_at":"2026-06-16T05:05:34.168127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surgery Partners Q1 revenue up 11.7% to $666.2M, net loss $24.9M, raises 2023 EBITDA guidance >$430M","bullets":["Revenue $666.2M (+11.7% YoY); same-facility revenue +10.3% (cases +5.3%, revenue per case +4.8%).","Net loss attributable to SGRY $24.9M vs net income $12.2M in Q1 2022; Adjusted EBITDA $90.1M (+17% from $77.1M).","Raises 2023 Adjusted EBITDA guidance to >$430M; Q1 free cash flow $20.5M, deployed $60M on five acquisitions.","New strategic partnerships with Intermountain Health and OhioHealth for expansion in new markets.","Net debt to EBITDA 4.3x; liquidity ~$800M ($245.5M cash + $545.9M revolver availability)."],"urls":{"canonical":"https://secwatch.observer/filing/0001638833-23-000067","json":"https://secwatch.observer/filing/0001638833-23-000067.json","markdown":"https://secwatch.observer/filing/0001638833-23-000067.md","text":"https://secwatch.observer/filing/0001638833-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000067/0001638833-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000067/sgry-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:05:34.168127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e40e70fa9743e18c774866f78d0da8d853a8bf9f","claim":"Surgery Partners, Inc. updated its full year 2023 guidance (raised).","evidence_excerpt":"The Company raises projected 2023 Adjusted EBITDA to be greater than $430 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000067/0001638833-23-000067-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"fe57fda0a0be615b8953602f31067d356794243c","claim":"Surgery Partners, Inc. reported first quarter ended March 31, 2023 results: revenue $666.2 million, net income $(24.9) million. Guidance raised.","evidence_excerpt":"a leading provider of surgical services, today announced financial results for the first quarter ended March 31, 2023. • Revenue increased 11.7% from the prior year period to $666.2 million ◦ Same-facility revenue increasing 10.3% • Net loss attributable to Surgery Partners, Inc. was $24.9 million ◦ Adjusted EBITDA of $90.1 million; 17% greater than the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883323000067/0001638833-23-000067-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$666.2 million"},{"label":"Net income","value":"$(24.9) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}